Minerva Neurosciences | NERV - Gross Profit On Sales


Minerva Neurosciences reported -4.27M in Gross Profit on Sales for its fiscal quarter ending in December of 2024.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 243.27M 14.49M Mar/2026
Adma Biologics USD 88.82M 13.19M Dec/2025
ALKERMES USD 331.33M 7M Mar/2026
AstraZeneca USD 12.61B 225M Mar/2026
BioCryst Pharmaceuticals USD 153.05M 4.16M Dec/2025
Bristol-Myers Squibb USD 8.41B 381M Dec/2025
Cipla INR 39.1B 2.54B Mar/2026
Clal Biotechnology ILS -857K 1.42M Jun/2022
Compugen USD 63.8M 63.56M Dec/2025
CSL USD 4.46B 2.71B Dec/2025
Eli Lilly USD 15.92B 1.33B Dec/2025
Esperion Therapeutics USD 140.59M 94.57M Dec/2025
GlaxoSmithKline GBP 5.75B 429M Mar/2026
Grifols EUR 766.49M 39.74M Dec/2024
Halozyme Therapeutics USD 297.47M 75.53M Mar/2026
Ionis Pharmaceuticals USD 243M 48M Mar/2026
J&J USD 17.24B 642M Mar/2026
Merck USD 10.85B 2.57B Dec/2025
Minerva Neurosciences -4.27M 26.79M Dec/2024
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Novartis USD 10.07B 184M Mar/2026
Novavax USD 125.04M 76.09M Dec/2025
Pfizer USD 11.04B 1.24B Mar/2026
Roche Holding CHF 22.09B 10.04B Dec/2025
Sanofi EUR 8.45B 1.31B Dec/2025
Takeda JPY 688.84B 101.71B Mar/2026
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024